AI Article Synopsis

  • This study analyzed the cost-effectiveness of using oral S-1 therapy instead of standard intravenous taxane therapy for treating first-line metastatic breast cancer.
  • Data from a randomized phase III trial (SELECT BC) was used, revealing that S-1 provided slightly better quality-adjusted life years (QALY) and lower overall costs compared to taxane treatment.
  • The findings indicate that S-1 therapy has a high likelihood of being cost-effective, with a 92% chance of being a viable option when considering a specific willingness to pay threshold for additional health benefits.

Article Abstract

Background: This study evaluated the cost-effectiveness of replacing standard intravenous therapy (taxane) with oral S-1 therapy for first-line metastatic breast cancer treatment.

Methods: This cost-effectiveness analysis was based on data from a randomized phase III trial (SELECT BC). As cost-effectiveness was a secondary endpoint of the SELECT BC trial, some of the randomized patients participated in an EQ-5D survey (N = 391) and health economic survey (N = 146). The EQ-5D responses, claims, and prescription data were collected for as long as possible until death. The expected quality-adjusted life years (QALY) obtained from each treatment were calculated using patient-level EQ-5D data, and the expected cost was calculated using patient-level claim data. The analysis was performed from the perspective of public healthcare payers.

Results: The estimated EQ-5D least-square means and 95% CI up to 48 months were 0.764 (95% CI, 0.741-0.782) and 0.742 (95% CI, 0.720-0.764) in the S-1 and taxane arms, respectively. The expected QALY was 2.11 for the S-1 arm and 2.04 for the taxane arm, with expected costs of JPY 5.13 million (USD 46,600) and JPY 5.56 million (USD 50,500), respectively. These results show that S-1 is cost-saving. According to probabilistic sensitivity analysis, S-1 was dominant with a probability of 63%. When the willingness to pay (WTP) value was JPY 5 million (USD 45,500) per QALY, the probability of being cost-effective was 92%.

Conclusions: Our results show that the introduction of oral S-1 therapy for metastatic breast cancer is highly likely to be cost-effective.

Trial Registration: UMIN CTR C000000416 . Registered on May 10, 2006.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5693567PMC
http://dx.doi.org/10.1186/s12885-017-3774-7DOI Listing

Publication Analysis

Top Keywords

s-1 therapy
12
metastatic breast
12
breast cancer
12
cost-effectiveness analysis
8
therapy first-line
8
first-line metastatic
8
randomized phase
8
phase iii
8
select trial
8
oral s-1
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!